SpyGlass Pharma reports four‑year interim results of its Bimatoprost Drug Pad‑IOL implant
+1 new source since this summary was written
SpyGlass Pharma announced that its first‑in‑human trial of the Bimatoprost Drug Pad‑IOL (BIM‑IOL) system showed a 37% mean reduction in intraocular pressure after four years. Of the 21 evaluable patients, 86% remained off all topical IOP‑lowering drops and 90% kept best‑corrected visual acuity of 20/25 or better, with no product‑related adverse events reported. The company said the study will continue through 2029 and it will pursue a 505(b)(2) New Drug Application with the FDA.
Why it matters
The data suggest the implant could address adherence challenges in glaucoma treatment, potentially expanding SpyGlass’s market opportunity and supporting future revenue forecasts (the company indicated it will work with the FDA toward commercialization).
Key facts
- 1The trial enrolled 23 patients across three dose groups (75 µg, 150 µg, 300 µg). investing.com
- 2At the four‑year assessment, 21 patients remained evaluable. investing.com
- 3Mean intraocular pressure fell 37% from 25.1 ± 2.5 mmHg at baseline to 15.9 ± 2.8 mmHg. investing.com
- 486% of patients (18 of 21) were off all topical IOP‑lowering drops. investing.com
- 590% of patients maintained best‑corrected distance visual acuity of 20/25 or better. investing.com
- 6No product‑related adverse events were reported during the four‑year period. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.